| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4794323
Max Phase: Preclinical
Molecular Formula: C23H20N4O2S
Molecular Weight: 416.51
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: COc1cc(-c2cnc3c(-c4cccc(NC(=O)C5CC5)c4)snc3c2)ccc1N
Standard InChI: InChI=1S/C23H20N4O2S/c1-29-20-11-14(7-8-18(20)24)16-10-19-21(25-12-16)22(30-27-19)15-3-2-4-17(9-15)26-23(28)13-5-6-13/h2-4,7-13H,5-6,24H2,1H3,(H,26,28)
Standard InChI Key: USWHRHQETHBPEE-UHFFFAOYSA-N
Associated Targets(Human)
Serine/threonine-protein kinase GAK 1150 Activities
Associated Targets(non-human)
dengue virus type 2 2400 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 416.51 | Molecular Weight (Monoisotopic): 416.1307 | AlogP: 4.96 | #Rotatable Bonds: 5 |
| Polar Surface Area: 90.13 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 2 |
| #RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 13.80 | CX Basic pKa: 3.86 | CX LogP: 3.81 | CX LogD: 3.81 |
| Aromatic Rings: 4 | Heavy Atoms: 30 | QED Weighted: 0.45 | Np Likeness Score: -1.34 |
References
| 1. Martinez-Gualda B,Saul S,Froeyen M,Schols D,Herdewijn P,Einav S,De Jonghe S. (2021) Discovery of 3-phenyl- and 3-N-piperidinyl-isothiazolo[4,3-b]pyridines as highly potent inhibitors of cyclin G-associated kinase., 213 [PMID:33497888] [10.1016/j.ejmech.2021.113158] |
Source
Source(1):